This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS
Cost analysis of biomarker testing for mismatch repair deficiency in node‐positive colorectal cancer. BJS 2008; 95: 868-875.
Published: 6th May 2008
Authors: E. Barrow, R. McMahon, D. G. Evans, E. Levine, J. Hill
Background
Microsatellite instability (MSI) in colorectal cancer is caused by defective DNA mismatch repair (MMR). It is present in 15 per cent of sporadic colorectal cancers owing to epigenetic mutL homologue 1 (MLH1) inactivation. The evidence suggests that patients with tumours caused by defective DNA MMR do not benefit from 5‐fluorouracil (5‐FU)‐based chemotherapy.
Method
The proportion of cancers with defective DNA MMR identified by MSI analysis or immunohistochemistry was calculated from published data. The cost of analysis was compared with the potential savings if 5‐FU‐based chemotherapy was not administered to these patients.
Results
Some 16·3 per cent of sporadic colorectal cancers had defective DNA MMR. Immunostaining for MLH1 and mutS homologue 2 (MSH2) had a sensitivity of 92·4 per cent and a specificity of 99·6 per cent for identifying MSI‐high tumours. The strongest predictive variable was right‐sidedness, with positive and negative predictive values of 0·329 and 0·948 respectively. If 5‐FU‐based chemotherapy were not administered, potential savings of up to £1·2 million per 1000 patients tested could be made. Costs would be higher if alternative chemotherapeutic regimens were substituted as a result of testing.
Conclusion
Knowledge of MMR status may enable participation in trials of non‐5‐FU‐based chemotherapy. The cost of MMR testing may be offset by more efficient use of chemotherapy. Copyright © 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Full text